From 3–6 May 2025, Nature Reviews Gastroenterology & Hepatology attended Digestive Disease Week in San Diego, USA. According to the organizers, more than 13,400 people were registered for the conference (in-person and online).

As usual, a wide array of sessions was available across basic, translational and clinical science in gastroenterology and hepatology with tantalizing insights into unpublished data from ongoing studies and interim trial results. For basic and translational sciences, cutting-edge talks covered a range of topics, including the small intestinal microbiome, advances in organoid technology and cellular plasticity in metaplasia. Clinical sessions addressed the evolving management of obesity, changes in the global incidence of inflammatory bowel disease, and interventions to reduce disparities and improve care for Native American populations and other minorities. Abstracts featured at the meeting included, among others, an interim analysis from the STENOVA trial, a phase IIa trial of a small molecule inhibitor (AGMB-129, an oral ALK5 inhibitor) for fibrostenotic Crohn’s disease and early insights into the safety, tolerability and pharmacodynamic effects of tolerizing nanoparticles (TPM502) for the treatment of coeliac disease.